HENDERSON MICHAEL THOMAS sold $2.0M of SYRE
HENDERSON MICHAEL THOMAS sold 20,000 shares of Spyre Therapeutics, Inc. (SYRE) at $100.00 ($2.00M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s open-market sale of 20,000 shares at $100/share is disclosed, with a stated pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific filing is unlikely to be a primary driver without additional company catalysts.
What to watch
Check for other insider transactions around the same period and whether there are concurrent corporate events (financing, trial updates) that could dominate price action.
Background
The article is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, Inc. (SYRE).
Ticker impact
Spyre Therapeutics director HENDERSON MICHAEL THOMAS filed a Form 4 selling 20,000 shares at $100/share under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.
The transaction is an open-market sale by a director and explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive value versus discretionary selling.
Market effects
No sector read-across; this is company-specific insider transaction disclosure.
None.
None.
Counterpoint
Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish fundamentals; traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.
- insiderHENDERSON MICHAEL THOMAS
Director who reported the sale of 20,000 shares.
